Krystal Biotech Inc (KRYS)

Quick ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash	US$ in thousands	344,865	373,966	345,786	359,006	358,328	373,241	275,875	140,745	161,900	186,409	218,720	269,303	341,246	286,614	329,527	402,172	268,269	282,369	291,678	180,225
Short-term investments	US$ in thousands	252,635	214,334	213,814	179,294	173,872	188,859	201,625	209,655	217,300	207,991	206,880	165,297	96,854	56,486	38,173	1,228	3,031	4,031	5,522	6,475
Receivables	US$ in thousands	104,700	97,298	103,236	46,467	42,040	9,316	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total current liabilities	US$ in thousands	101,995	89,527	71,851	47,589	33,094	27,583	23,898	35,076	28,847	28,032	34,427	60,437	25,736	35,779	18,119	9,144	15,452	7,198	5,831	4,061
Quick ratio		6.88	7.66	9.23	12.29	17.35	20.72	19.98	9.99	13.15	14.07	12.36	7.19	17.02	9.59	20.29	44.12	17.56	39.79	50.97	45.97

December 31, 2024 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($344,865K + $252,635K + $104,700K) ÷ $101,995K
= 6.88

Krystal Biotech Inc's quick ratio, which measures the company's ability to meet its short-term obligations with its most liquid assets, has fluctuated over the period under consideration.

From March 31, 2020, to December 31, 2020, the quick ratio was relatively high, indicating a strong ability to cover short-term liabilities with its liquid assets. However, there was a significant decrease in the quick ratio by June 30, 2021, suggesting potential liquidity concerns.

Subsequently, there were fluctuations in the quick ratio, reaching a low point on March 31, 2022. This could raise concerns about the company's ability to meet its short-term obligations. However, there was a slight improvement by June 30, 2022.

The quick ratio continued to fluctuate but generally remained at moderate levels up to December 31, 2024. While the quick ratio improved from its lowest points, it is still important for Krystal Biotech Inc to closely monitor and manage its liquidity positions to ensure it can meet its short-term obligations effectively.